---
title: "COMPASS Pathways plc (CMPS.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CMPS.US/overview.md"
symbol: "CMPS.US"
name: "COMPASS Pathways plc"
parent: "https://longbridge.com/en/quote/CMPS.US.md"
datetime: "2026-04-15T23:13:21.484Z"
locales:
  - [en](https://longbridge.com/en/quote/CMPS.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CMPS.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CMPS.US/overview.md)
---

# COMPASS Pathways plc (CMPS.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 33 Broadwick Street, London, Greater London, United Kingdom |
| Website | [compasspathways.com](https://compasspathways.com) |

## Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

## Key Executives

| Name | Title |
|------|-------|
| Kabir Kumar Nath | CEO & Director |
| Gino Santini | Independent Chairman |
| Teri Loxam | Chief Financial Officer |
| Guy Goodwin | Chief Medical Officer |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
| Lars Christian Wilde | Senior Advisor |
| Annalisa Lisa Mary Jenkins | Independent Non-Executive Director |
| Daphne Karydas | Independent Director |
| David York Norton | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| RTW Investments, LP | 6.79% | 2025-12-31 |
| Deep Track Capital, LP | 5.69% | 2025-12-31 |
| AtaiBeckley Inc. | 3.70% | 2026-01-21 |
| GMT Capital Corp. | 2.21% | 2025-12-31 |
| The Toronto-Dominion Bank | 1.96% | 2025-12-31 |
| ARK Investment Management LLC | 1.67% | 2025-12-31 |
| George Jay Goldsmith | 1.59% | 2025-03-31 |
| UBS Asset Management AG | 1.58% | 2025-12-31 |
| Ekaterina Malievskaia | 1.57% | 2025-03-31 |
| Two Sigma Investments, LP | 1.28% | 2025-12-31 |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**